Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib neoadjuvant therapy in early-stage TNBC with high TILs
ChiCTR2500105033Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Pathological complete remission (pCR) rate. Started Jun 2025; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500105033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105033.